Drug Discovery

#AI #Drug development #Drug discovery

Iktos teams up with Sygnature Discovery on development project  

Artificial intelligence company Iktos has announced a collaboration with drug discovery company Sygnature Discovery in a deal designed to accelerate drug discovery and development.  The three-year deal will see Sygnature using Iktos’ de novogenerative design software Makya to facilitate rapid and efficient design of novel… Read More

#News

#AI #Data #Drug discovery

BenevolentAI achieves third milestone with AstraZeneca

AstraZeneca has identified an additional target for its idiopathic pulmonary fibrosis (IPF) pipeline using an AI system designed by drug discovery company BenevolentAI. It is now the third target from that collaboration that has been identified using BenevolentAI’s platform. AstraZeneca is using the company’s Benevolent Platform across two disease areas… Read More

#News

#Covid-19 #Drug discovery #Genetics

Biotechs partner to understand genetics of long Covid   

A partnership between life sciences companies PrecisionLife and Sano Genetics aims to drive insights into the genetics of long Covid and potentially identify new treatments.    The companies will analyse Sano Genetics’ data of 3,000 adults suffering from long Covid symptoms using PrecisionLife’s combinatorial analytics platform… Read More

#Covid-19 #News

#CRISPR #CRISPR screening #CRISPR-Cas9 #Drug discovery

CRISPR-Cas9 screening: a powerful approach to drug discovery

Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More

#News

#Automation / robotics #Biologics #Biopharma #Drug development

Driving production in biologics development with automation

Drug development technology has evolved rapidly in recent years, and with the industry, advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. Since most biologics are large molecules, they may prove challenging to develop and manufacture on the large scale. Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Events #Medtech #Public health

Back in-person for 2022: LSX World Congress returns

For the last seven years, the LSX World Congress has bought together biotech, medtech and healthtech executives to connect with the capital, intelligence, innovation, and partners they need to grow their businesses. Back in-person for 2022, the 8th Congress takes place 10-11 May at 133 Houndsditch in London. … Read More

#News #Trending News

#Clinical research #Drug development #Drug discovery #Supply chain

Achieving faster drug lifecycle management 

Eugene Polini, Technical Key Account Manager at Datwyler examines the challenges drug developers are facing to speed up production lifecycles and what solutions are available to them.  While people around the world hope to never see another global pandemic in their lifetimes, it is the responsibility of pharmaceutical manufacturers to… Read More

#News

#AI #Drug discovery

DNDi and BenevolentAI to tackle dengue in drug discovery project  

Artificial intelligence (AI) company BenevolentAI and not-for-profit R&D organisation Drugs for Neglected Disease initiative (DNDi) have launched a joint research project to tackle dengue, one of the world’s most prevalent infectious diseases.  Dengue represents one of the top 10 threats to global public health worldwide. Despite an… Read More

#News

#AI #Drug discovery #Small molecules

X-Chem launches small molecule discovery platform

Artificial intelligence (AI) company X-Chem has announced that its drug discovery platform XD3 is now available to biopharma partners and clients. XD3 is the company’s small molecule drug discovery platform and combines data generated through DNA-encoded library (DEL) screening, along with analytical and predictive capabilities offered by A-Chem’s AI platform,… Read More

#News

#Drug development #Finance #Investment

Boyds records growth following investment strategy  

Global drug development consultancy Boyds has reported strong financial growth following a two-year strategy to expand its business.  Boyds saw an increase of over 20% year-on-year in annual revenue in the wake of increased demand for drug development expertise across the UK, US, and Europe. … Read More

#News

#Assays #Biopharmaceuticals #Biotherapeutics #Drug development #Drug discovery

PerkinElmer releases assay kits for more effective biotherapeutics 

PerkinElmer has announced two ready-to-use HTRF and AlphaLISA no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing.   Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities… Read More

#News

#AI #Business Intelligence Group #Drug discovery

X-Chem VP recognised for AI contributions  

Noor Shaker, the Senior Vice President and General Manager for DNA technology company X-Chem, has been named a winner in the Artificial Intelligence Excellence Awards programme from Business Intelligence Group.   Shaker was one of six receiving an individual award from Business Intelligence Group, which recognises people and organisations applying… Read More

#News

#Drug discovery #Innovation #Whitepaper

Whitepaper: Maximising outsourcing models beyond time and cost

In this whitepaper, we will expand on key factors – cost, time, and innovation – and illustrate how integrating these factors will minimise the challenges and ensure success in outsourcing drug discovery. Learn about: Opportunities, options, and outsourcing of drug discovery programs Hidden costs vs. hidden value Impact on… Read More

#News

#AI #Drug discovery

Iktos teams up with Ono Pharmaceuticals on AI project  

Artificial intelligence (AI) company Iktos has announced a collaboration with Ono Pharmaceuticals focused on expediting drug discovery for pre-clinical candidates.   The collaboration will see Iktos apply its de novo ligand and structure-based generative modelling technologies and software Makaya to complement Ono’s drug discovery capabilities. More so, Iktos… Read More

#News

#Clinical trial #Drug development #Drug discovery #Therapeutics

Rani Therapeutics initiates Phase I study osteoporosis drug 

Rani Therapeutics, a clinical stage biotherapeutics company focused on the oral delivery of biologics, has initiated a Phase I study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via capsule.  The first subject has been administered RT-102… Read More

#News